Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers

Clinical Cancer Research

Volumn 21, Issue 8, 2015, Pages 1904-1915

  Oberthuer, André ^a   Juraeva, Dilafruz ^b   Hero, Barbara ^a   Volland, Ruth ^a   Sterz, Carolina ^a   Schmidt, Rene ^c   Faldum, Andreas ^c   Kahlert, Yvonne ^a   Engesser, Anne ^a   Asgharzadeh, Shahab ^d   Seeger, Robert ^d   Ohira, Miki ^e   Nakagawara, Akira ^e   Scaruffi, Paola ^f   Tonini, Gian Paolo ^g   Janoueix Lerosey, Isabelle ^h   Delattre, Olivier ^h   Schleiermacher, Gudrun ^h   Vandesompele, Jo ⁱ   Speleman, Frank ⁱ   Noguera, Rosa ^j   Piqueras, Marta ^j   Bénard, Jean ^k   Valent, Alexander ^k   Avigad, Smadar ^l,m   Yaniv, Isaac ^l,m   Grundy, Richard G ⁿ   Ortmann, Monika ^a   Shao, Chunxuan ^b   Schwab, Manfred ^b   Eils, Roland ^b,o   Simon, Thorsten ^a   Theissen, Jessica ^a   Berthold, Frank ^a   Westermann, Frank ^b   Brors, Benedikt ^b   Fischer, Matthias ^a   more..

^a UNIVERSITY OF COLOGNE   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d CHILDREN S HOSPITAL LOS ANGELES   (United States)

^e CHIBA CANCER CENTER   (Japan)

^f UNIVERSITY OF GENOA   (Italy)

^g UNIVERSITY OF PADOVA   (Italy)

^h INSTITUT CURIE   (France)

ⁱ GHENT UNIVERSITY HOSPITAL   (Belgium)

^j UNIVERSITY OF VALENCIA   (Spain)

^k INSTITUT GUSTAVE ROUSSY   (France)

^l SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^m TEL AVIV UNIVERSITY   (Israel)

ⁿ UNIVERSITY OF LEICESTER   (United Kingdom)

^o UNIVERSITY OF HEIDELBERG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER PROGNOSIS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; EVENT FREE SURVIVAL; GENE EXPRESSION PROFILING; HUMAN; INTERMEDIATE RISK PATIENT; KAPLAN MEIER METHOD; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; NEUROBLASTOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STRATIFICATION; VALIDATION PROCESS; CLINICAL TRIAL; CLUSTER ANALYSIS; FEMALE; FOLLOW UP; GENE EXPRESSION REGULATION; GENETICS; MALE; MORTALITY; MULTICENTER STUDY; PROGNOSIS; REGRESSION ANALYSIS; REPRODUCIBILITY; RISK FACTOR;

TUMOR MARKER;

BIOMARKERS, TUMOR; CLUSTER ANALYSIS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; NEUROBLASTOMA; PROGNOSIS; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS;

EID: 84927628636     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0817     Document Type: Article

References (37)

1. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma Lancet 2007;369: 2106-20.
2. London WB, Castleberry RP, Matthay KK, Look AT, Seeger RC, Shimada H, et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol 2005;23: 6459-65.
3. Evans AE, D'Angio GJ, Randolph J. A proposed staging for children with neuroblastoma. Children's cancer study group A. Cancer 1971;27: 374-8.
4. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11: 1466-77.
5. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984;224: 1121-4.
6. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985;313: 1111-6.
7. Spitz R, Hero B, Ernestus K, Berthold F. Deletions in chromosome arms 3p and 11q are new prognostic markers in localized and 4s neuroblastoma. Clin Cancer Research 2003;9: 52-8.
8. Attiyeh EF, London WB, Mosse YP, Wang Q, Winter C, Khazi D, et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 2005;353: 2243-53.
9. Look AT, Hayes FA, Nitschke R, McWilliams NB, Green AA. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med 1984;311: 231-5.
10. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B, et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 1999;86: 364-72.
11. Ohira M, Oba S, Nakamura Y, Isogai E, Kaneko S, Nakagawa A, et al. Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas. Cancer Cell 2005;7: 337-50.
12. Asgharzadeh S, Pique-Regi R, Sposto R, Wang H, Yang Y, Shimada H, et al. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene ampli fication. J Natl Cancer Inst 2006;98: 1193-203.
13. Oberthuer A, Berthold F, Warnat P, Hero B, Kahlert Y, Spitz R, et al. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol 2006;24: 5070-8.
14. Vermeulen J, De Preter K, Naranjo A, Vercruysse L, Van Roy N, Hellemans J, et al. Predicting outcomes for children with neuroblastoma using a multi-gene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol 2009;10: 663-71.
15. De Preter K, Vermeulen J, Brors B, Delattre O, Eggert A, Fischer M, et al. Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature. Clin Cancer Res 2010;16: 1532-41.
16. Oberthuer A, Hero B, Berthold F, Juraeva D, Faldum A, Kahlert Y, et al. Prognostic impact of gene expression-based classification for neuroblastoma. J Clin Oncol 2010;28: 3506-15.
17. Shi L, Campbell G, Jones WD, Campagne F, Wen Z, Walker SJ, et al. The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol 2010;28: 827-38.
18. Ambros PF, Ambros IMB Siop Europe Neuroblastoma Pathology Marrow G Bone. Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines. Med Pediatr Oncol 2001;37: 492-504.
19. Oberthuer A, Juraeva D, Li L, Kahlert Y, Westermann F, Eils R, et al. Comparison of performance of one-color and two-color gene-expression analyses in predicting clinical endpoints of neuroblastoma patients. Pharmacogenomics J 2010;10: 258-66.
20. Smyth G. Limma: linearmodels formicroarray data. In: Bioinformatics and computational biology solutions using R and bioconductor. New York: Springer; 2005. p. 397-420.
21. R:Core-Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2013. Available from: http://www.R-project.org/.
22. Guyon I, Weston J, Barnhill S, Vapnik V. Gene selection for cancer classification using support vector machines. Machine Learning 2002;46: 389-422.
23. Wei JS, Greer BT, Westermann F, Steinberg SM, Son CG, Chen QR, et al. Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Cancer Res 2004;64: 6883-91.
24. Collett D. Strategy for model selection. In: Modelling survival data in medical research. London, United Kingdom: Chapman & Hall; 1994. p. 78-83.
25. Simon T, Spitz R, Faldum A, Hero B, Berthold F. New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status. J Pediatr Hematol Oncol 2004;26: 791-6.
26. Oberthuer A, Theissen J, Westermann F, Hero B, Fischer M. Molecular characterization and classification of neuroblastoma. Future Oncol 2009; 5: 625-39.
27. Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 2009;27: 289-97.
28. Baker DL, Schmidt ML, Cohn SL, Maris JM, London WB, Buxton A, et al. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med 2010;363: 1313-23.
29. Rubie H, De Bernardi B, Gerrard M, Canete A, Ladenstein R, Couturier J, et al. Excellent outcome with reduced treatment in infants with non-metastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1. J Clin Oncol 2011;29: 449-55.
30. Hero B, Simon T, Spitz R, Ernestus K, Gnekow AK, Scheel-Walter HG, et al. Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. J Clin Oncol 2008; 26: 1504-10.
31. Chen QR, Bilke S, Wei JS, Greer BT, Steinberg SM, Westermann F, et al. Increased WSB1 copy number correlates with its over-expression which associates with increased survival in neuroblastoma. Genes Chromosomes Cancer 2006;45: 856-62.
32. Garcia I, Mayol G, Rodriguez E, Sunol M, Gershon TR, Rios J, et al. Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma. Mol Cancer 2010;9: 277.
33. Decock A, Ongenaert M, Hoebeeck J, De Preter K, Van Peer G, Van Criekinge W, et al. Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers. Genome Biol 2012;13: R95.
34. Fredlund E, Ringner M, Maris JM, Pahlman S. High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma. Proc Natl Acad Sci U S A 2008;105: 14094-9.
35. Westermann F, Muth D, Benner A, Bauer T, Henrich KO, Oberthuer A, et al. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Genome Biol 2008;9: R150.
36. Theissen J, Boensch M, Spitz R, Betts D, Stegmaier S, Christiansen H, et al. Heterogeneity of the MYCN oncogene in neuroblastoma. Clin Cancer Res 2009;15: 2085-90.
37. Klein JP, Logan B, Harhoff M, Andersen PK. Analyzing survival curves at a fixed point in time. Stat Med 2007;26: 4505-19.